Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRIS vs CNSY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRIS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–3 Matrix Metrics)

CRIS Overall Winner 6-Pillar Tally: CRIS 4 – 0 CNSY (2 Tie) Matrix Metrics: CRIS 6 – 3 CNSY

As of Nov 16, 2026, Curis Inc (CRIS) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRIS carries a Unified Composite Score of 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin), whereas CNSY carries 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. CRIS 38.7/100 SELL), CRIS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-833.4% vs. N/A operating margin) and revenue trajectory (-66.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: CRIS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9); meanwhile CNSY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRIS vs CNSY
CRIS NASDAQ Head-to-Head Winner
Curis Inc
Biological Products, (No Disgnostic Substances)
$0.44
-1.07% 1D
Market Cap $3.8M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 11.40β · 269% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 15.0 Fund 41.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -37.9%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $0.58 · SMA50: $0.75
CNSY US Equity
CNSY
Institutional Equity
$0.72
-24.24% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.54β · 228% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.8%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $1.25 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (CRIS 4 – 0 CNSY)

Columns: Metric · CRIS · CNSY
1. Valuation Multiples CRIS
Forward P/E N/M N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CRIS
Revenue Growth (YoY) -66.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $4.3M N/A
Market Cap $3.8M N/A
3. Profitability & Quality CRIS
Gross Margin N/A N/A
Operating Margin -833.4% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -693.9% N/A
4. Balance Sheet & Cash Flow CRIS
Cash Generation (TTM) -$36M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.0M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRIS (6) vs CNSY (3)
Institutional Metric CRIS CNSY Criterion Row Edge
Market Capitalization
Scale
$3.8M N/A Larger Scale CRIS
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple CRIS
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-66.0% N/A Higher Growth CRIS
Operating Margin (TTM)
Profitability
-833.4% N/A Higher Margin CRIS
Net Profit Margin
Profitability
0.0% N/A Higher Margin CRIS
Return on Equity (ROE)
Capital Efficiency
-693.9% N/A Higher ROE CRIS
52-Week Range Position
Momentum
4% ($0–$7) 8% ($0–$4) Stronger Trend CNSY
Beta / 30D Volatility
Risk Regime
11.40β · 269% Vol 2.54β · 228% Vol Lower Realized Risk CNSY
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 47.6 / 100 (HOLD) Higher Composite CNSY
Trailing 12M Revenue (USD)
Operating Scale
$4.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$36M EBITDA ($4.0M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRIS +65.78 pp
CRIS: +8.13% · CNSY: -57.65%
3M Horizon CRIS +2.52 pp
CRIS: -74.11% · CNSY: -76.63%
6M Horizon CNSY +11.9 pp
CRIS: -91.45% · CNSY: -79.55%
1Y Horizon CNSY +11.9 pp
CRIS: -91.45% · CNSY: -79.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRIS vs CNSY. Trailing 12-month operating profitability (CRIS -833.4% vs CNSY N/A) and valuation multiples (CRIS N/M vs CNSY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRIS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.3M
Gross MarginN/A
Op. Margin-833.4%
ROE / Fwd P/E-693.9% · N/M
CNSY ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRIS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRIS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNSY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CNSY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRIS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -833.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CNSY Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRIS vs CNSY Key Questions & Quantitative Answers

As of Nov 16, 2026, Curis Inc (CRIS) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRIS carries a Unified Composite Score of 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin), whereas CNSY carries 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. CRIS 38.7/100 SELL), CRIS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-833.4% vs. N/A operating margin) and revenue trajectory (-66.0% vs. N/A YoY). Technical & Structure Timing Caution: CRIS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9); meanwhile CNSY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRIS leads the Growth & Scale pillar: CRIS posts -66.0% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (N/A gross margin, -833.4% operating margin), compared with CNSY at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CRIS generates $4.3M in USD-normalized revenue versus N/A for CNSY. In operating R&D and SG&A reinvestment, CRIS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNSY.

CRIS screens cheaper on headline valuation multiples. CRIS trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas CNSY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRIS (-693.9% ROE) versus CNSY (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CRIS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.40β · 269% Vol realized risk). By comparison, CNSY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.54β · 228% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.